MARKET

PGEN

PGEN

Precigen Inc
NASDAQ
4.290
+0.050
+1.18%
After Hours: 4.280 -0.01 -0.23% 19:13 02/06 EST
OPEN
4.280
PREV CLOSE
4.240
HIGH
4.460
LOW
4.280
VOLUME
3.84M
TURNOVER
--
52 WEEK HIGH
5.23
52 WEEK LOW
1.110
MARKET CAP
1.52B
P/E (TTM)
-3.0628
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at PGEN last week (0126-0130)?
Weekly Report · 6d ago
Precigen (PGEN) Is Down 5.7% After Consensus Backs PAPZIMEOS As New First-Line RRP Therapy
Simply Wall St · 01/30 23:38
Weekly Report: what happened at PGEN last week (0119-0123)?
Weekly Report · 01/26 10:36
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Becomes Preferred First Line RRP Treatment
Simply Wall St · 01/24 15:35
Why Precigen (PGEN) Is Up 5.3% After PAPZIMEOS Becomes First-Line RRP Standard of Care – And What's Next
Simply Wall St · 01/21 16:19
New Expert Consensus Published in The Laryngoscope Recommends PAPZIMEOS (zopapogene imadenovec) as the New Standard of Care First-Line Treatment for Adults with Recurrent Respiratory Papillomatosis
PR Newswire · 01/20 13:05
Weekly Report: what happened at PGEN last week (0112-0116)?
Weekly Report · 01/19 10:44
Assessing Precigen (PGEN) Valuation After PAPZIMEOS Commercial Momentum And EMA Milestone
Simply Wall St · 01/15 06:30
More
About PGEN
Precigen, Inc. is a discovery and clinical-stage biopharmaceutical company developing gene and cell therapies for improving outcomes for patients with unmet medical needs. The Company’s proprietary technology platforms develop product candidates designed to target urgent and intractable diseases in its core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It has developed a pipeline of therapies across multiple indications. The Company’s segments include Biopharmaceuticals and Exemplar. The Biopharmaceuticals segment is primarily comprised of the Company's legal entities as well as royalty interests in therapeutics and therapeutic platforms from companies not controlled by the Company. The Exemplar is composed of Exemplar Genetics LLC, doing business as Precigen Exemplar, its wholly owned subsidiary focused on developing research models and services for healthcare research applications.

Webull offers Precigen Inc stock information, including NASDAQ: PGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PGEN stock methods without spending real money on the virtual paper trading platform.